Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Page values for "Cyclosporine"

From Pharmacopedia
More actions

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringCyclosporine (ciclosporin)
brandStringSandimmune, Neoral (modified microemulsion, increased bioavailability), Gengraf, Restasis (ophthalmic)
structureFile
classesList of String, delimiter: ,[[:Category:Calcineurin_inhibitors|Calcineurin inhibitor]] [[:Category:Immunosuppressants|Immunosuppressant]]
mechanismString
usesString'"`UNIQ--vote-00000A8C-QINU`"', '"`UNIQ--vote-00000A8D-QINU`"', '"`UNIQ--vote-00000A8E-QINU`"', '"`UNIQ--vote-00000A8F-QINU`"', '"`UNIQ--vote-00000A90-QINU`"'
starting_doseStringTransplant: 5-10 mg/kg/d divided BID, titrated to trough levels (typically 100-300 ng/mL depending on regimen and post-transplant interval); ophthalmic Restasis 0.05% one drop BID
preparationsStringSandimmune 25, 100 mg capsules; Neoral 25, 100 mg modified soft gel; 100 mg/mL oral solution; 50 mg/mL IV; Restasis 0.05% ophthalmic emulsion
fda_maxStringTransplant: regimen-specific
pill_idText
routesList of String, delimiter: ,Oral IV ophthalmic
onsetStringDays for immunosuppressive effect
durationStringDosing-frequency dependent
halflifeString~8-27 hours (highly variable across the population)'"`UNIQ--ref-00000A91-QINU`"'
bioavailabilityStringSandimmune: highly variable (~30%); Neoral microemulsion: ~50%, less variable; '''Sandimmune and Neoral are NOT bioequivalent and not interchangeable''''"`UNIQ--ref-00000A92-QINU`"'
pregnancyStringUsed in transplant pregnancy when continued immunosuppression is required; reassuring data overall but careful monitoring needed.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString[[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warning''' for risk of malignancy and serious infection; nephrotoxicity, hypertension, and immunosuppression-associated complications'"`UNIQ--ref-00000A93-QINU`"'